

24 INTRODUCTION

25 Two SARS-CoV-2-related pangolin coronaviruses, GD/2019 and GX/2017, were
26 identified prior to the COVID-19 outbreak (1, 2). The respective isolates, termed
27 pCoV-GD01 and GX_P2V, were cultured in 2020 and 2017, respectively (2, 3). The
28 infectivity and pathogenicity of these isolates have been studied (4-6). The
29 pCoV-GD01 isolate, which has higher homology with SARS-CoV-2, can infect and
30 cause disease in both golden hamsters and hACE2 mice (4). In contrast, GX_P2V was
31 found to be highly attenuated in previously tested animals like golden hamsters,
32 BALB/c mice and two types of human ACE2-transgenic (hACE2) mouse (5, 6). We
33 previously reported that the early passaged GX_P2V isolate was actually a cell
34 culture-adapted mutant, named GX_P2V(short_3UTR), which possesses a
35 104-nucleotide deletion at the 3'-UTR (6). In this study, we analyzed its adaptive
36 mutation in cell culture, and assessed its pathogenicity in a unique CAG-hACE2
37 mouse model. We found that GX_P2V(short_3UTR) can infect hACE2 mice, with
38 high viral loads detected in both lung and brain tissues, which are correlated with the
39 strong expression of hACE2 in these tissues. This infection resulted in 100%
40 mortality in the hACE2 mice. We surmise that the cause of death may be linked to the
41 occurrence of late brain infection.

42 RESULTS

43 We first analyzed the adaptive mutations of the GX_P2V(short_3UTR) mutant in
44 cell cultures by random cloning and sequencing. The passaged mutant was cloned
45 through two successive plaque assays. Eight viral clones were chosen for

46 next-generation sequencing (National Genomics Data Center of China, GSA:
47 CRA014225). These clones, when compared with the genome of the original mutant
48 (6), all shared four identical mutations: ORF1ab_D6889G, S_T730I, S_K807N, and
49 E_A22D (Supporting Information, Table S1). Clone 7, named as GX_P2V C7, was
50 randomly selected for the evaluation of viral pathogenicity in hACE2 mice (Figure
51 1A). The hACE2 mouse model expressing human ACE2 under control of the CAG
52 promoter was developed using random integration technology by Beijing SpePharm
53 Biotechnology Company.

54 Next, we assessed whether GX_P2V C7 could cause disease in hACE2 mice by
55 monitoring daily weight and clinical symptoms. A total of four 6 to 8-week-old
56 hACE2 mice were intranasally infected with a dosage of 5×10^5 plaque-forming units
57 (pfu) of the virus. Four mice inoculated with inactivated virus and four mock-infected
58 mice were used as controls. Surprisingly, all the mice that were infected with the live
59 virus succumbed to the infection within 7-8 days post-inoculation, rendering a
60 mortality rate of 100% (Figure 1B). The mice began to exhibit a decrease in body
61 weight starting from day 5 post-infection, reaching a 10% decrease from the initial
62 weight by day 6 (Figure 1C). By the seventh day following infection, the mice
63 displayed symptoms such as piloerection, hunched posture, and sluggish movements,
64 and their eyes turned white. The criteria for clinical scoring of the mice and the daily
65 clinical scores post-infection with GX_P2V C7 are provided in the Supporting
66 Information, Figure S1.

67 We then evaluated the tissue tropism of GX_P2V C7 in hACE2 mice. Using the

68 infection method described above, eight hACE2 mice were infected, eight mice were
69 inoculated with inactivated virus, and another eight mock-infected mice were used as
70 controls. The organs of four randomly selected mice in each group were dissected on
71 days 3 and 6 post-infection for quantitative analysis of viral RNA and titer. We
72 detected significant amounts of viral RNA in the brain, lung, turbinate, eye, and
73 trachea of the GX_P2V C7 infected mice (Figure 1D), whereas no or a low amount of
74 viral RNA was detected in other organs such as the heart, liver, spleen, kidneys,
75 tongue, stomach, and intestines. Specifically, in lung samples, we detected high viral
76 RNA loads on days 3 and 6 post-infection, with no significant difference between
77 these two time points (~ 6.3 versus ~ 5.8 $\text{Log}_{10}[\text{copies}/\text{mg}]$). In brain samples, on day
78 3 post-infection, viral RNA was detected in all four infected mice, with an average
79 value of 5.4 $\text{Log}_{10}[\text{copies}/\text{mg}]$. Notably, by day 6 post-infection, we detected
80 exceptionally high viral RNA loads (~ 8.5 $\text{Log}_{10}[\text{copies}/\text{mg}]$) in the brain samples
81 from all four infected mice (Figure 1D). On days 3 and 6 post-infection, the viral
82 RNA loads in the turbinate were similar, approximately 4.1 and 3.9 $\text{Log}_{10}[\text{copies}/\text{mg}]$,
83 respectively. The viral RNA loads in the trachea and eyes of the mice surpassed the
84 limit of detection only on day 6 post-infection, with values of 2.6 and 3.8
85 $\text{Log}_{10}[\text{copies}/\text{mg}]$, respectively. Regarding the infectious viral titers, lung tissues at
86 day 3 post-infection had a value of ~ 1.8 $\text{Log}_{10}[\text{pfu}/\text{mg}]$, which decreased to ~ 0.5
87 $\text{Log}_{10}[\text{pfu}/\text{mg}]$ by day 6. Importantly, the highest infectious titers were detected in the
88 brain on day 6, which was significantly greater than that on day 3 (~ 0.9 vs ~ 4.8
89 $\text{Log}_{10}[\text{pfu}/\text{mg}]$) (Figure 1E). Additionally, there were no significant differences in the

90 infectious titers in the turbinate between day 3 (~ 0.9 Log₁₀[pfu/mg]) and day 6 (~ 1.2
91 Log₁₀[pfu/mg]) (Figure 1E). By day 6, approximately 2.0 Log₁₀[pfu/mg] was detected
92 in the eyes of two mice. Neither inactivated GX_P2V C7 nor mock infection caused
93 death or any clinical symptoms in the mice (Figure 1B-C and Supporting Information,
94 Figure S2). In summary, in the mice infected with live virus, the viral load in the
95 lungs significantly decreased by day 6; both the viral RNA loads and viral titers in the
96 brain samples were relatively low on day 3, but substantially increased by day 6. This
97 finding suggested that severe brain infection during the later stages of infection may
98 be the key cause of death in these mice.

99 To determine the mechanisms underlying GX_P2V C7-induced death in hACE2
100 mice, we examined the pathological changes, presence of viral antigens, and cytokine
101 profiles in the lung and brain tissues of the mice on days 3 and 6 post-infection
102 (Figure 1F-G, and Supporting Information, Figure S3 and S4). On both days,
103 compared to those of control mice, the lungs of infected mice showed no significant
104 pathological alterations, with only minor inflammatory responses due to slight
105 granulocyte infiltration (Figure 1F). On day 3 post-infection, shrunken neurons were
106 visible in the cerebral cortex of the mice. By day 6, in addition to the shrunken
107 neurons, there was focal lymphocytic infiltration around the blood vessels, although
108 no conspicuous inflammatory reaction was observed (Figure 1G). Upon staining for
109 viral nucleocapsid protein via immunohistochemistry, viral antigens were detected in
110 both the lungs and brains on days 3 and 6 post-infection, with extensive viral antigens
111 notably present in the brain on day 6 (Figure 1F-G). These findings align with the

112 viral RNA load assessments in the lung and brain tissues (Figure 1D). We also
113 performed a Luminex cytokine assay to detect 31 cytokines/chemokines in the lung
114 and brain tissues of the mice (Supporting Information, Figure S3 and S4). Consistent
115 with the pathological findings, there were slight increases or decreases in the levels of
116 many cytokines/chemokines in lung and brain tissues compared to those in control
117 tissues, but the levels of key inflammatory factors, such as IFN- γ , IL-6, IL-1 β , and
118 TNF- α , did not significantly change. In brief, these analyses revealed that GX_P2V
119 C7 infection in hACE2 mice did not lead to severe inflammatory reactions, a finding
120 that aligns with previous reports by Zhengli Shi's group using GX_P2V infection in
121 two different hACE2 mouse models (5), as well as our own findings in the golden
122 hamster model (6).

123 **DISCUSSION**

124 To the best of our knowledge, this is the first report to analyze the cell-adapted
125 mutations of pangolin coronavirus GX_P2V, and to show it can cause mortality in
126 hACE2 mice. Our findings are evidently inconsistent with those of Zhengli Shi *et al.*
127 (5), who tested the virulence of GX_P2V in two different hACE2 mouse models. It is
128 very likely that the high pathogenicity of GX_P2V C7 in our hACE2 mice is due to
129 the strong expression of hACE2 in the mouse brain. Under normal circumstances,
130 both human and mouse brains exhibit low expression of ACE2 (6, 7). Furthermore,
131 while the company has not yet published a paper detailing the construction and
132 characterization of this hACE2 mouse model, we are notified that these hACE2 mice
133 have abnormal physiology, as indicated by relatively reduced serum triglyceride,

134 cholesterol, and lipase levels, compared to those of wild-type C57BL/6J mice. Thus,
135 the outcomes from the mouse infections in this study have no correlation with human
136 infections, and do not alter the fundamental nature of GX_P2V(short_3UTR) as being
137 highly attenuated.

138 Currently, there is an urgent need for the development of broadly protective
139 vaccines against pan-SARS-CoV-2, yet the emergence of the next SARS-CoV-2
140 variant is unpredictable. The pangolin coronavirus GX_P2V(short_3UTR), which
141 shares a certain degree of homology with SARS-CoV-2, may be valuable in assessing
142 the effectiveness of broad-spectrum COVID-19 vaccine candidates against unknown
143 future variants. Moreover, our lethal mouse infection model presents no obvious
144 inflammatory responses in the main affected organs, the lungs and brain, thereby
145 providing an alternative model to evaluate antiviral drugs' efficacy in inhibiting viral
146 replication *in vivo*. In summary, our study provides a unique perspective on the
147 pathogenicity of GX_P2V and offers an invaluable model for assessing the efficacy of
148 drugs and vaccines against SARS-CoV-2.

149

150 **REFERENCES**

- 151 1. Liu P, Chen W, Chen JP. Viral Metagenomics Revealed Sendai Virus and
152 Coronavirus Infection of Malayan Pangolins (*Manis javanica*). *Viruses*. 2019 Oct
153 24;11(11).
- 154 2. Lam TT, Jia N, Zhang YW, Shum MH, Jiang JF, Zhu HC, et al. Identifying
155 SARS-CoV-2-related coronaviruses in Malayan pangolins. *Nature*. 2020

156 Jul;583(7815):282-5.

157 3. Xiao K, Zhai J, Feng Y, Zhou N, Zhang X, Zou JJ, et al. Isolation of
158 SARS-CoV-2-related coronavirus from Malayan pangolins. *Nature*. 2020
159 Jul;583(7815):286-9.

160 4. Huang XY, Chen Q, Sun MX, Zhou HY, Ye Q, Chen W, et al. A pangolin-origin
161 SARS-CoV-2-related coronavirus: infectivity, pathogenicity, and cross-protection by
162 preexisting immunity. *Cell Discov*. 2023 Jun 17;9(1):59.

163 5. Liu MQ, Lin HF, Li J, Chen Y, Luo Y, Zhang W, et al. A SARS-CoV-2-Related
164 Virus from Malayan Pangolin Causes Lung Infection without Severe Disease in
165 Human ACE2-Transgenic Mice. *J Virol*. 2023 Feb 28;97(2):e0171922.

166 6. Lu S, Luo S, Liu C, Li M, An X, Li M, et al. Induction of significant neutralizing
167 antibodies against SARS-CoV-2 by a highly attenuated pangolin coronavirus variant
168 with a 104nt deletion at the 3'-UTR. *Emerg Microbes Infect*. 2023
169 Dec;12(1):2151383.

170 7. Natalia Alenina, Michael Bader. ACE2 in Brain Physiology and Pathophysiology:
171 Evidence from Transgenic Animal Models. *Neurochem Res*. 2019
172 Jun;44(6):1323-1329. doi: 10.1007/s11064-018-2679-4.

173 8. Meng-Yuan Li, Lin Li, Yue Zhang, Xiao-Sheng Wang. Expression of the
174 SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. *Infect Dis
175 Poverty*. 2020 Apr 28;9(1):45. doi: 10.1186/s40249-020-00662-x.

176 **ACKNOWLEDGEMENTS**

177 This work was supported by NSFC-MFST project (China–Mongolia) (grant number

178 32161143027), National Key R&D Program of China (2021YFC2301804) and
179 Biosafety Special Program (No. 19SWAQ 13).

180 **ETHICS STATEMENT**

181 All animals involved in this study were housed and cared for in an AAALAC
182 (Association for Assessment and Accreditation of Laboratory Animal Care) accredited
183 facilities. The procedure for animal experiments (IACUC-2019-0027) was approved
184 by the Institutional Animal Care and Use Committee of the Fifth Medical Center,
185 General Hospital of the Chinese People's Liberation Army, and complied with IACUC
186 standards.

187 **AUTHOR CONTRIBUTIONS**

188 L.Song conceived and designed the study and wrote the manuscript. L.W., S.Liu,
189 S.Lu., and S.Luo. performed the experiments and analyzed the data. X.A., H.F., W.C.,
190 E.L. and Y.T. analyzed the data and edited the manuscript. L.W. and L.Song wrote the
191 manuscript and all the authors approved the manuscript.

192 **CONFLICT OF INTERESTS**

193 The authors declare no competing interests.

194 **SUPPORTING INFORMATION**

195 Additional Supporting Information for this article can be found online at

196 **DATA AVAILABILITY**

197 All the data supporting the findings of this study are available within the article and
198 the Supporting Information, or from the corresponding author upon reasonable
199 request.

200 **ORCID**






201 Lihua Song, <https://orcid.org/0000-0002-7299-5719>

202 **Figure 1: Characterization of a lethal infection model in human**
203 **ACE2-transgenic mice caused by the attenuated SARS-CoV-2-related pangolin**
204 **coronavirus GX_P2V C7.** **A** Mutations in GX_P2V C7 compared to the
205 GX_P2V(short_3UTR) isolate (NCBI accession number: MW532698). The four
206 identical mutations are shown in bold. **B** Survival of hACE2 transgenic mice
207 following intranasal infection with GX_P2V C7 ($n = 4$), inactivated GX_P2V C7
208 (i-C7, $n = 4$), and mock infection ($n = 4$). The number of deceased mice on each
209 specific day is annotated on the left of the survival curve. **C** Percentage of initial
210 weight of hACE2 transgenic mice after intranasal infection with GX_P2V C7 ($n = 4$),
211 i-C7 ($n = 4$), and mock infection ($n = 4$). The statistical significance of the differences
212 between mock-infected ($n = 4$, blue dots) and GX_P2V C7-infected ($n = 4$, red dots)
213 or i-C7-infected mice ($n = 4$, orange dots) at 6 or 7 dpi are shown. The error bars
214 represent the means \pm SDs. **D** Quantification of GX_P2V N gene copies in heart, liver,
215 spleen, lung, kidney, tongue, intestine, stomach, trachea, brain, eye, and turbinate
216 homogenates at 3- and 6-day post-infection (dpi) ($n = 4$ per group). The limit of
217 detection (LOD) for viral RNA loads in the original samples was $\text{Log}_{10}[10^2$
218 $\text{copies/mg}]$. The error bars represent the means of $\text{Log}_{10}[\text{copies/mg}] \pm$ SDs. The
219 significances of the comparisons in the lung, brain, and turbinate are shown. **E**
220 Infectious viral titers in lung, brain, eye, and turbinate homogenates were measured
221 by plaque forming assay at 3 and 6 dpi ($n = 4$ per group). The statistical significance
222 of the differences in the lung, brain, and turbinate are shown. The error bars represent
223 means of $\text{Log}_{10}[\text{pfu/mL}] \pm$ SDs. **F, G** Hematoxylin and eosin (H&E) staining and

224 immunohistochemical (IHC) staining with an anti-SARS-CoV-2 N-specific antibody
225 (SARS-CoV-2) revealed viral antigen-positive cells (brown) in the lung (**F**) and brain
226 (**G**), as shown at high magnification in the inset. Scale bars, 500 μm (**F**) and 1 mm
227 (**G**), respectively. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, $P > 0.05$, not
228 significant (ns); two-way ANOVA followed by Sidak's multiple comparison test.

A

| Mutation | Codon change | Substitution | CDS Location |
|--------------|--------------|--------------|--------------|
| 1807 A to G | GGA to GGG | | ORF1ab |
| 6501 C to U | ACA to AUA | T to I | ORF1ab |
| 19694 C to U | ACA to AUA | T to I | ORF1ab |
| 20930 A to G | GAU to GGU | D to G | ORF1ab |
| 23727 C to U | ACU to AUU | T to I | S |
| 23959 A to C | AAA to AAC | K to N | S |
| 26274 C to A | GCU to GAU | A to D | E |
| 29227 C to U | UAC to UAU | | N |

C**D****F****B****E****G**